Apr.12 -- Chris Chen, chief executive officer of Wuxi Biologics (Cayman) Inc., a pharmaceutical company developing and manufacturing antibody drugs, discusses how the coronavirus outbreak has been affecting his business, and the company's programs related to the Covid-19 virus. He speaks with Haslinda Amin and Rishaad Salamat on "Bloomberg Markets: Asia."